{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:58:26Z","timestamp":1761562706482,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016476","name":"Cardiovascular Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.carrev.2019.12.018","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T20:29:18Z","timestamp":1576614558000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years"],"prefix":"10.1016","volume":"21","author":[{"given":"Soeren","family":"Mattke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bentele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kandzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.carrev.2019.12.018_bb0005","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.carrev.2019.12.018_bb0010","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.amjcard.2018.07.040","article-title":"Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery","volume":"122","author":"Iantorno","year":"2018","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.carrev.2019.12.018_bb0015","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","article-title":"Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease","volume":"138","author":"Bangalore","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.carrev.2019.12.018_bb0020","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/j.jacc.2018.09.019","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents: BIOFLOW V 2-year results","volume":"72","author":"Kandzari","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.carrev.2019.12.018_bb0025","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jacc.2016.12.005","article-title":"Trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries","volume":"69","author":"Masoudi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.carrev.2019.12.018_bb0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.carrev.2018.11.006","article-title":"Health economic evaluation of an ultrathin, bioresorbable polymer sirolimus-eluting coronary stent compared to a thin, durable polymer everolimus-eluting stent","volume":"20","author":"Mattke","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"issue":"4","key":"10.1016\/j.carrev.2019.12.018_bb0035","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2125.2012.04421.x","article-title":"Overview of pharmacoeconomic modelling methods","volume":"75","author":"Ademi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.carrev.2019.12.018_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"PharmacoEconomics"},{"issue":"6","key":"10.1016\/j.carrev.2019.12.018_bb0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.carrev.2019.12.018_bb0050","first-page":"717","article-title":"Length of stay following percutaneous coronary intervention: an expert consensus document update from the society for cardiovascular angiography and interventions","volume":"92","author":"Seto","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2019.12.018_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12872-016-0190-x","article-title":"Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study","volume":"16","author":"Fox","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"10.1016\/j.carrev.2019.12.018_bb0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s12325-015-0264-7","article-title":"A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia","volume":"32","author":"Henk","year":"2015","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.carrev.2019.12.018_bb0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamacardio.2018.4566","article-title":"Cost-effectiveness of Canakinumab for prevention of recurrent cardiovascular events","volume":"4","author":"Sehested","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.carrev.2019.12.018_bb0070","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2008.01.042","article-title":"Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model","volume":"51","author":"Garg","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2019.12.018_bb0075","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2016.05.049","article-title":"Predicting in-hospital mortality in patients with acute myocardial infarction","volume":"68","author":"McNamara","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9973","key":"10.1016\/j.carrev.2019.12.018_bb0080","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(14)61932-2","article-title":"Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study","volume":"385","author":"Nallamothu","year":"2015","journal-title":"The Lancet"},{"year":"2015","series-title":"Trends in Observed Adult Inpatient Mortality for High-Volume Conditions, 2002\u20132012","author":"Anika","key":"10.1016\/j.carrev.2019.12.018_bb0085"},{"year":"2015","series-title":"Hospital Inpatient Mortality Indicators for California","author":"Quality AfHRa","key":"10.1016\/j.carrev.2019.12.018_bb0090"},{"key":"10.1016\/j.carrev.2019.12.018_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.puhe.2016.09.032","article-title":"Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction (SAMI) project","volume":"143","author":"Plakht","year":"2017","journal-title":"Public Health"},{"issue":"4","key":"10.1016\/j.carrev.2019.12.018_bb0100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"10.1016\/j.carrev.2019.12.018_bb0105","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jcin.2018.01.277","article-title":"Mortality following nonemergent, uncomplicated target lesion revascularization after percutaneous coronary intervention: an individual patient data pooled analysis of 21 randomized trials and 32,524 patients","volume":"11","author":"Palmerini","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"10124","key":"10.1016\/j.carrev.2019.12.018_bb0110","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.carrev.2019.12.018_bb0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.athoracsur.2015.11.032","article-title":"The Society of Thoracic Surgeons adult cardiac surgery database: 2016 update on outcomes and quality","volume":"101","author":"D\u2019Agostino","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"10175","key":"10.1016\/j.carrev.2019.12.018_bb0120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(18)32467-X","article-title":"Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial","volume":"393","author":"Zaman","year":"2019","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.carrev.2019.12.018_bb0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4244\/EIJ-D-18-00336","article-title":"Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial","volume":"14","author":"Kok","year":"2018","journal-title":"EuroIntervention"},{"issue":"10149","key":"10.1016\/j.carrev.2019.12.018_bb0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial","volume":"392","author":"Pilgrim","year":"2018","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.carrev.2019.12.018_bb0135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial","volume":"11","author":"Lefevre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"10.1016\/j.carrev.2019.12.018_bb0140","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.117.028191","article-title":"India and the coronary stent market: getting the price right","volume":"135","author":"Wadhera","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.carrev.2019.12.018_bb0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1377\/hlthaff.2016.1627","article-title":"National health expenditure projections, 2016\u201325: price increases, aging push sector to 20 percent of economy","volume":"36","author":"Keehan","year":"2017","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.carrev.2019.12.018_bb0150","article-title":"Medical device innovation in the era of the affordable care act: the end of sexy","volume":"6","author":"Mattke","year":"2016","journal-title":"Rand Health Quarterly"},{"issue":"7","key":"10.1016\/j.carrev.2019.12.018_bb0155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCULATIONAHA.118.035236","article-title":"Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk","volume":"139","author":"Baron","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carrev.2019.12.018_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1377\/hlthaff.22.2.17","article-title":"The business case for quality: case studies and an analysis","volume":"22","author":"Leatherman","year":"2003","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.carrev.2019.12.018_bb0165","series-title":"Bundled Payments for Care Improvement (BPCI) Initiative: General Information","volume":"2016","author":"Medicare Cf, Services M","year":"2016"},{"year":"2013","series-title":"Stata: Release 13. Statistical Software","author":"StataCorp","key":"10.1016\/j.carrev.2019.12.018_bb0170"},{"issue":"4","key":"10.1016\/j.carrev.2019.12.018_bb0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/ehjqcco\/qcw019","article-title":"Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study","volume":"2","author":"Janzon","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"10.1016\/j.carrev.2019.12.018_bb0180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMra0912134","article-title":"Myocardial infarction due to percutaneous coronary intervention","volume":"364","author":"Prasad","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919308164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919308164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:17:31Z","timestamp":1761560251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838919308164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1553838919308164"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2019.12.018","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2019.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}